[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
December 1995

Misuse of Nonophthalmic and Ophthalmic Drops Due to Packaging Similarity-Reply

Author Affiliations

Richmond, Va

Arch Ophthalmol. 1995;113(12):1579. doi:10.1001/archopht.1995.01100120110028

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In reply  Currently, the American Academy of Ophthalmology endorses the uniform use of a color-coding system for the caps and labels of the following products: topical carbonic anhydrase inhibitors, orange; anti-infectives, tan; anti-inflammatories/steroids, pink; mydriatics, red; nonsteroidal anti-inflammatory drugs, gray; miotics/pilocarpine, green; and β-blockers, yellow. The objective of the uniform color-coding system is to help patients distinguish between various ocular medications, thereby minimizing the risk of selecting an inappropriate medication and averting major medical problems.The Committee on Drugs of the American Academy of Ophthalmology evaluates ophthalmic medications for uniform color-coding according to the nature of the disease being treated, the product's side-effect profile, and the risk for serious sequelae should a product be inadvertently switched with another.In the case of the hypertonic solution and topical anesthetic products cited in the letter above, the Academy, through its Committee on Drugs, does not have colorcoding recommendations. Since the color-coding

First Page Preview View Large
First page PDF preview
First page PDF preview